Allison Winter, MD

home / authors / allison-winter-md

Allison Winter, MD, is a member of the Department of Hematology and Medical Oncology at the Cleveland Clinic in Ohio.

Articles

Allison Winter, MD

Dr Winter on the Role of Treatment History in Richter Transformation

Allison Winter, MD
May 19th 2025

Allison Winter, MD, emphasizes the importance of carefully evaluating treatment history in patients with Richter transformation from CLL.

Read More

Allison Winter, MD

Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL

Allison Winter, MD
June 24th 2024

Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.

Read More

Allison Winter, MD, Department of Hematology and Medical Oncology, Cleveland Clinic

Dr Winter on Real-World Outcomes With Liso-Cel in Richter Transformation

Allison Winter, MD
June 20th 2024

Allison Winter, MD, discusses data from a retrospective analysis evaluating real-world outcomes with liso-cel in patients with Richter transformation.

Read More

Allison Winter, MD, of Cleveland Clinic

Dr. Winter on Emerging Agents in CLL

Allison Winter, MD
December 3rd 2020

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Read More

Allison Winter, MD

Dr. Winter on the Role of Frontline Targeted Therapies in CLL

Allison Winter, MD
November 30th 2020

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the role of frontline targeted therapies in chronic lymphocytic leukemia.

Read More

Allison Winter, MD, of Cleveland Clinic

Dr. Winter on the Utility of PI3K Inhibitors in CLL

Allison Winter, MD
November 18th 2020

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Read More

Latest Updated Articles

Alexis LeVee, MD
Published: May 14th 2025 | Updated: May 30th 2025
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer